anti-TCRVbeta Chimeric Antigen Receptors (CARs)

Reference number 11203

Sectors: Biotechnology, Medical research

Industries: Therapeutics

A chimeric antigen receptor (CAR) construct specific for a T-cell receptor (TCR) beta-chain variable region subunit of a T cell.

Proposed use

For use in immunotherapy, for treating or preventing cancer, autoimmune disease or any disease characterized by the presence of pathogenic T cells.

Problem addressed

Current CAR-based immunotherapies eliminate either the whole or 50% of healthy T cells, thus rendering patients profoundly immunosuppressed. Our anti-TCRVbeta Chimeric Antigen Receptor immunotherapy would leave >90% of the T cell immunity intact, thus reducing considerably the probability of life-threatening infections.

Technology overview

Within a healthy T cell population, each cell expresses 1 of 22 different types of TCRVbeta chains. Pathological T cells express the same TCRVbeta which is only expressed in <10% of normal T cells.

We have developed anti-TCRVbeta Chimeric Antigen Receptors which can target pathological T cells in a highly selective manner, leaving >90% of the patient’s T cells and T cell-dependent immunity intact.

Benefits

  • Targets and selectively kills pathogenic T cells, e.g. T cell lymphomas and autoimmune diseases
  • Leaves >90% of healthy T cells intact
  • Leaves T cell dependent immunity intact
  • Reduces probability of life-threatening infections

Intellectual property information

A PCT application was filled in August 2023. The priority date is August 2022.

Inventor

Professor Anastasios Karadimitris

Co-Director Centre for Haematology, Professor of Haematology
Faculty of Medicine, Department of Immunology and Inflammation

Visit personal site

Contact us about this technology


Contact

Dr Rachel Spruce

Industry Partnerships and Commercialisation Executive, Medicine

Rachel is Industry Partnerships and Commercialisation Officer for the Faculty of Medicine.

Contact Rachel

[email protected]

Related technologies

A cytokine for wound healing and scar reduction

A cytokine for wound healing and scar reduction

A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics Find out more

Active delivery of Zinc Fingers for in vivo enhancement of gene regulation

Active delivery of Zinc Fingers for in vivo enhancement of gene regulation

A universal method to enhance control of gene expression in vivo with artificial gene-regulatory transcription factors (TFs). Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...